OncoSec OMS ElectroChemotherapy for Head and Neck Cancer Shows Enhanced Quality of Life in Two Randomized Phase III Studies

Data Presented at the 8th International Conference on Head and Neck Cancer Demonstrate Equivalent Disease Control and Survival, and Improved Functional Outcomes and Quality of Life Compared to Surgery

 

SAN DIEGO, CA — July 23, 2012 — OncoSec Medical Inc. (OTCBB:ONCS), a company developing the advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, announced data from an interim analysis of two randomized Phase III clinical trials, HNBE-01 and HNBE-02, using electrochemotherapy to treat locally recurrent and second primary squamous cell carcinoma of the head and neck (SCCHN). The data are being presented July 22-24 at the 8th International Conference on Head and Neck Cancer in Toronto, Canada. A link to the abstract can be found here.

In these studies, electrochemotherapy was compared against surgery for quality of life, safety, survival and local control at eight months, where local control is defined as destruction of the treated tumor without evidence of reappearance of the tumor at the treatment site. The data show OMS ElectroChemotherapy achieved the primary endpoint of preserving quality of life compared to surgery, and appears to be safe and comparable to surgery in achieving control in locally recurrent or second primary SCCHN. This therapy represents a viable alternative to potentially major surgical interventions for this patient population, where recurrent tumors in SCCHN usually have a poor prognosis with a local control rate of 40-50 percent and frequently associated loss of organ function.

Paul Goldfarb, M.D., Consulting Medical Director of OncoSec overseeing the Phase III studies, said, “Despite the early termination of this study, delayed interim analysis of these data clearly demonstrated there was equivalence in safety, local control at eight months and survival between electrochemotherapy and surgery, with a benefit of quality of life and function for patients who received electrochemotherapy.”

OncoSec is evaluating the regulatory strategy alternatives for the most optimal path to market clearance based on the available Phase III and previously announced Phase IV data. Concurrently, the company is seeking partnering opportunities as it begins to approach the FDA and other regulatory bodies with product registration plans.

Punit Dhillon, President and CEO of OncoSec, said, “Interim analysis of these two Phase III studies, and the recently released data from the Phase IV study carried out in Europe, has demonstrated that the primary endpoint of maintaining quality of life was achieved. In addition, OMS ElectroChemotherapy appears to provide a potentially important treatment alternative to surgery that may address hard-to-treat tumors where there exists a particular need to preserve function and quality of life. These data strongly support our partnering efforts for the OMS ElectroChemotherapy program.”

 

Study Design

HNBE-01 and HNBE-02 were designed as two open-label pivotal studies in which 214 patients with locally recurrent or second primary tumors, anterior and posterior to the tonsillar pillar, respectively, and amenable to surgical resection, were randomized 1:1 between surgery (control group) and electrochemotherapy (treatment group). The primary endpoint for these studies was quality of life, as measured by the Performance Status Scale for Head and Neck Cancer (PSSHN). Secondary endpoints were safety, local control at eight months and survival. For the treatment group, patients received local injection of bleomycin followed by electroporation. Radiation or neck dissection was permitted when warranted.

These studies were initiated in 2004 and subsequently closed in 2007, and were conducted at 22 sites in the United States, Canada, Eastern and Western Europe. Of the 214 enrolled subjects, 130 were randomized into HNBE-01 and 84 into HNBE-02. This study was terminated at the interim point following an independent data monitoring committee review; however, all treated patients were followed for up to two years to evaluate safety and efficacy. At the time of this analysis, there were a total of 98 evaluable subjects, 58 from HNBE-01 and 40 from HNBE-02.

 

Efficacy and Quality of Life

There were no statistically significant differences between time to death or local control rate at eight months between the control and experimental groups for HNBE-01 or HNBE-02 or the combination of both studies. Median time to death was statistically indistinguishable between surgery at 209 days versus 231 days for electrochemotherapy (p=0.55). Local tumor control at eight months was achieved in 92% of control group patients versus 90% of electrochemotherapy patients.

Quality of life was evaluated using the performance status scale for head and neck cancer patients (PSSHN), a functional outcome measurement assessing the ability to swallow, normalcy of diet and ability to eat in public. Assessment of quality of life by the PSSHN score showed a mean score of 269 at baseline versus 248 at eight months for the control group (p=0.036) versus 257 at baseline versus 249 at eight months for the electrochemotherapy group (p=0.59). While the scores in the electrochemotherapy group remained relatively unchanged at eight months, the surgery group in each trial showed a statistically significant decrease in overall function. The preservation of function and quality of life in the treatment group may be the result of the ability of OMS ElectroChemotherapy to spare surrounding vital tissue and reduce removal or destruction of additional tissue.

 

Safety

Early termination of these studies was recommended by the data monitoring committee following an interim review of safety data at the midway point of enrollment for HNBE-01 and HNBE-02. The interim analysis of long-term follow-up data at up to two years indicates there were no safety issues relating to electrochemotherapy, as reflected by the statistically significant equivalence between the groups in time to death. The most frequently reported adverse events, which were pain, nausea and local edema, were also equivalent for both groups of patients. There were no adverse experiences related to device performance observed among the 98 patients with squamous cell carcinoma of the head and neck who were evaluated, and no procedures were stopped as a result of device malfunction.

 

About OMS ElectroChemotherapy (Formerly SECTA)

On May 29, 2007 the Data Monitoring Committee (DMC) overseeing both the HNBE-01 and HNBE-02 studies recommended that enrollment of both studies be terminated, citing concerns regarding efficacy and safety, including mortality rates and enrollment futility. In the review by the DMC of interim data, the totality of the data indicated an unfavorable benefit to risk profile for the ElectroChemotherapy treatment arm relative to the surgery arm (control arm). As a result, the DMC suggested that the studies be stopped and no further subject enrollment be continued. Based on this recommendation, both studies were halted. The treated patients were followed up to two years to further evaluate safety and efficacy, as per protocol, but no additional data analysis was performed until recently by OncoSec.

Upon OncoSec’s acquisition of these programs and other assets in 2011, OncoSec conducted a complete analysis of the data. This analysis indicated that there were no statistically significant differences between time to death or duration of local control between the control or ElectroChemotherapy experimental arms in either the HNBE-01 or HNBE-02 trials, or the combined groups across studies. Furthermore, none of the other parameters examined, including demographics, time since original diagnosis, prior therapies or tumor stage, showed any significant statistical difference between these parameters. The most frequent side effects were pain 35.4% for patients undergoing surgery and 46% for those treated with electrochemotherapy (all grades). Other items raised by the DMC were also evaluated and the Company is confident these can be, or have already been, addressed.

SAN DIEGO, CA — June 19, 2012 — OncoSec Medical Inc. (OTCBB:ONCS), a company developing the OncoSec Medical System (OMS) ElectroOncology therapies to treat advanced-stage solid tumors, announced the Commissioner of Patents, Commonwealth of Australia Patent Office recently granted a new Method of Use patent (Patent Application No. 2007224275, “Method and Device for Treating Microscopic Residual Tumors Remaining in Tissues Following Surgical Resection”) for the company’s OMS ElectroOncology treatment platform. The issuance of this patent has the potential to expand OncoSec’s market opportunities for minimally invasive and surgical procedures to treat solid tumors, as an adjunct therapy to earlier-stage cancers. Specifically, it allows OMS technology to be used to treat the margins of solid tumors following surgical resection.

One of the methods of treating solid tumors, which represent the majority of all cancer incidences, is surgical removal of the tumor along with removal of healthy tissue surrounding the main tumor mass. The purpose of removing this additional tissue is to ensure that peripheral cancerous cells are also eliminated in order to prevent recurrence. However, the removal of this healthy tissue may result in function loss and have potentially detrimental cosmetic effects. This jeopardizes a patient’s quality of life.

OMS ElectroChemotherapy is an investigational therapy being evaluated to reduce the rate of cancer recurrence without quality of life side effects. As a potential adjunct to surgery, this therapeutic approach involves removal (using a scalpel) of the tumor mass, without removal of excess healthy tissue, followed by treatment with OMS ElectroChemotherapy. This approach has been shown to selectively kill cancer cells that may exist in the surrounding tissue, which may result in a reduced rate of recurrence and the potential to complement standard-of-care surgical procedures as an alternative to surgery alone.

Punit Dhillon, OncoSec’s President and CEO, commented, “The issuance of this patent opens the possibility for improving surgical outcomes in cancer therapy. There is a tremendous unmet clinical need, especially for advanced cancer where recurrence rates associated with surgery remain high.Treatment of margin tissue with our therapy potentially expands the market for our product beyond those indications we are currently pursuing for the use of the technology. We envision that surgical margins could be routinely treated with our therapy, providing increased benefit to patients.”

About OncoSec Medical Inc.

OncoSec Medical Incorporated is a biopharmaceuticalcompany developing advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers and metastatic disease. OMS ElectroOncology therapies address an unmet medical need and represent apotential solution for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from traditional cancer treatments. OncoSec’s core technology is based upon its proprietary use of an electroporation platform, to dramatically enhance the delivery and uptake of a locally delivered DNA-based immuno-cytokine or a chemotherapeutic agent. Treatment of various solid cancers using these targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec’s clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy targeting lethal skin cancers. More information is available at www.oncosec.com.

* * *

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward looking statements.” Forward looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties which may cause ourresults to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Phase IV Study Demonstrates Local Tumor Control in 94% of Primary and 57% of Recurrent Tumors and Enhanced Quality of Life in Patients Treated with OMS ElectroChemotherapy

SAN DIEGO, CA, April 23, 2012 — OncoSec Medical Inc. (OTCBB:ONCS), which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, today announced positive interim analysis of data from 81 subjects in a Phase IV study of primary and locally recurrent squamous cell carcinoma of the head and neck (HNSCC) treated with OMS ElectroChemotherapy in Europe. The study demonstrated the therapy’s ability to provide local tumor control and quality of life outcomes that compare favorably to standard outcomes associated with surgery. These results were presented at the 5th European Conference on Head and Neck Oncology in Poznan, Poland on Friday, April 20, 2012.

The primary goal of this phase IV head and neck cancer study was to assess the ability of the OMS ElectroChemotherapy to control growth or recurrence of the cancer eight months following treatment, equivalent to surgery as compared to historical controls, with respect to primary (new) tumors and locally recurrent tumors. In this interim analysis, local tumor control was achieved in 46/49 (94%) primary tumors and 12/21 (57%) recurrent tumors. This meant that there was no recurrence of the tumors during the monitoring period. These were excellent results that were on par with the expected outcomes of surgery. Furthermore, evaluation of safety using the OMS ElectroChemotherapy for this patient population demonstrated that the treatment was safe and well-tolerated with no grade three or higher adverse events related to treatment reported during this study.

In addition, the secondary endpoint of preservation of organ function and appearance using validated quality of life instruments demonstrated a positive outcome. The functional outcome measurement to evaluate quality of life assesses the ability to swallow, normalcy of diet, and ability to eat in public and is often assessed by the Performance Status Scale for Head and Neck cancer (PSSHN); general quality of life was assessed by the European Organization for Research and Treatment of Cancer Core QOL questionnaire (EORTC QLQ). Treated patients showed a mean overall score of 264 at baseline vs. 249 at eight months (p=0.3412), indicating no significant difference in quality of life following treatment with OMS ElectroChemotherapy. This is an excellent outcome; if the patient had been treated with surgery, the expectation and historical experience would result in a greater degradation of function and quality of life for these patients as determined by the PSSHN and EORTC QLQ scores. Therefore, treatment with OMS ElectroChemotherapy provided a significant benefit in maintaining quality of life while achieving an equivalent local control compared to surgery. Additional secondary endpoints for this study included evaluation of pharmacoeconomic factors (hospital costs, extent of medical interventions, and medication use) as well as clinical performance of the OncoSec Medical System and applicator. The conclusions regarding these endpoints were positive and will be reviewed in a final publication.

“There is a significant unmet clinical need for an alternative to surgery that selectively destroys cancer cells without harming normal healthy tissue,” said Dr. Paul Goldfarb, medical director of OncoSec and principal investigator of this study. “This therapy provides patients who would typically be subjected to disfiguring surgery with potentially improved treatment outcomes.”

Punit Dhillon, President and CEO, said, “Our OMS ElectroChemotherapy treatment provided safe and clinically beneficial outcomes for patients while maintaining quality of life. We strongly believe in the clinical relevance of the OMS ElectroChemotherapy program and believe these results will help prospective partners to better define the broad applicability and market opportunity for this novel treatment.”

This Phase IV pre-marketing study was conducted in 11 European clinical centers of excellence with institutional review board and competent authority approval and carried out under standard good clinical practices using OncoSec’s OMS ElectroChemotherapy treatment platform for primary and recurrent head and neck cancer.

About Head and Neck Cancer

Head and neck cancers are difficult to treat because of the damage to adjacent healthy tissue that occurs during surgical resection. Nevertheless, surgery is often the first treatment approach for a primary or first occurrence of a head and neck cancer if its size and location is amenable to this approach. Treatment may also involve radiation therapy where the tumor is either more difficult to access or complete removal is questionable. The recurrence rate of primary head and neck cancer following surgery has been reported to be as high as 50% depending on the size and location of the tumor using conventional therapy. There is consequently an urgent need for a treatment alternative with the ability to improve local tumor control, thereby reducing the rate of recurrence and improving survival. In addition, many patients treated with surgery and/ or radiation will experience problems associated with loss of function, such as swallowing and speech, and cosmetic disfigurement, significantly impacting quality of life for these patients. If a recurrence occurs, treatment may again involve surgery, radiation and/or chemotherapy. At this point, the goal of local tumor control is to maintain quality of life, and potentially salvage and cure the patient. The challenge is to achieve these goals while minimizing the injury to adjacent healthy tissue and maintaining quality of life and functional outcomes. Each year, there are approximately 150,000 new cases of head and neck cancer in Europe, resulting in 65,000 deaths. Worldwide, approximately 560,000 cases of head and neck cancer are diagnosed, and 300,000 patients are expected to die annually.

About ElectroChemotherapy

OncoSec’s ElectroChemotherapy enables local application of a chemotherapeutic agent, bleomycin, directly into a tumor and the healthy margin of tissue surrounding the tumor and selectively kills cancerous cells. As opposed to surgery, this therapeutic approach can avoid removal of healthy tissue, providing beneficial appearance, organ function and quality of life outcomes.

About OncoSec Medical Inc.

OncoSec Medical Incorporated (OTCBB: ONCS) develops novel OMS ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapieshave achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec’s clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy. More information is available at www.oncosec.com. Additional information may also be found at OncoSec’s Facebook , Twitter, and LinkedIn sites.

* * *

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward looking statements.” Forward looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties which may cause ourresults to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

New Analysis of Phase III and IV Head & Neck Cancer Results

SAN DIEGO, CA, March 22, 2012 — OncoSec Medical Incorporated. (OTCBB:ONCS), which is developing its advanced-stage OncoSec Medical System(OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that the company has been selected to present data from its Phase III and IV head and neck cancer studies at two upcoming conferences. Data from the Phase IV study carried out in Europe has been selected for a poster session and special oral presentation at the 5th European Conference on Head and Neck Oncology. In addition, data from the Phase III study carried out in the United States has been selected for a poster presentation at the 8th International Head and Neck Cancer Conference.

OncoSec’s most advanced stage treatment platform, OMS ElectroChemotherapy, is a targeted ablation therapy, which utilizes the OMS to locally deliver bleomcyin to the tumor. This treatment platform preferentially kills targeted cancer cells while sparing surrounding normal healthy tissue. OMS ElectroChemotherapy has been developed up to Phase III clinical trials in the United States for the treatment of recurrent head and neck cancer and in Phase I/II for the treatment of recurrent breast cancer. In addition, Phase IV pre-marketing studies to support the commercialization of the OMS system in Europe were also performed for the treatment of primary and recurrent head and neck cancers and cutaneous skin cancers.

“Since acquiring the OMS ElectroChemotherapy assets in March 2011, we have been working diligently to compile and analyze data from the Phase III and IV studies carried out in the United States and Europe. We are excited that we will now have the opportunity to share this data with the public in the coming months,” said Punit Dhillon, President and CEO. “With this data, we expect to finalize our clinical development plan and move forward with commercializing the OMS ElectroChemotherapy platform with a partner, either regionally or globally.”

The Phase IV head and neck cancer results, carried out in Europe, will be presented at:
The 5th European Conference on Head and Neck Oncology
Poznan, Poland
April 18-21, 2012

Special Poster Session and Presentation
“Interim analysis of an open labeled, single arm multicenter study of electrochemotherapy in recurrent head and neck cancer”

The 8th International Head and Neck Cancer Conference
Toronto Convention Center
Toronto, Canada
July 21-25, 2012

Poster Session
“Interim analysis of two randomized Phase 3 trials comparing electrochemotherapy to surgery in recurrent head and neck cancer”

About OMS ElectroChemotherapy

Through its asset acquisition, OncoSec has accumulated a significant database of clinical data in a variety of tumor types using the OMS ElectroChemotherapy therapeutic approach. To date OMS ElectroChemotherapy has been tested in several clinical trials ranging from Phase I through Phase IV conducted in 13 countries across over 50 sites. Human data has been collected in over 400 patients with cancers ranging from basal and squamous cell carcinomas, melanoma, adenocarcinoma, Kaposi’s sarcoma, pancreatic, hepatic, oral, and head and neck cancers. OMS ElectroChemotherapy utilizes electroporation to locally deliver the chemotherapeutic drug bleomycin to treat solid tumors. A distinctive feature of the OMS ElectroChemotherapy treatment platform is both the preservation of healthy tissue and killing of cancerous cells in the lesion and at the margins of the tumor. It is anticipated that the system may therefore afford advantages over surgery in preserving function and improving the quality of life for cancer patients who would otherwise face significant morbidity associated with cancer surgery or other treatment modalities.

About Head and Neck Cancer

Most head and neck cancers are found in people over age 40. Men are two to three times more likely than women to have head and neck cancer,although rates in women have been rising along with their growing use of tobacco and alcohol. The number of new cases of head and neck cancers in the United States was 70,490 in 2008, accounting for about 3% of adult malignancies and the worldwide incidence exceeds half a million cases annually. It is estimated that approximately $3.1 billion is spent in the United States each year on treatment for head and neck cancers. Head and neck cancers encompass a diverse group of uncommon tumors that frequently are aggressive in their biologic behavior. Moreover, patients with a head and neck cancer often develop a second primary tumor, in part secondary to common risk factors. In North America and Europe, the tumors usually arise from the oral cavity, oropharynx, or larynx, whereas nasopharyngeal cancer is more common in the Mediterranean countries and in the Far East. In Southeast China and Taiwan, head and neckcancer, specifically nasopharyngeal cancer is the most common cause of death in young men.

About OncoSec Medical Inc.

OncoSec Medical Incorporated (OTCBB: ONCS) develops novel OMS ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapieshave achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec’s clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy. More information is available at www.oncosec.com. Additional information may also be found at OncoSec’s Facebook , Twitter, and LinkedIn sites.

* * *

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward looking statements.” Forward looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties which may cause ourresults to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

SAN DIEGO, CA, March 13, 2012 — OncoSec Medical Incorporated (OTCBB:ONCS), which is developing its advanced-stage OncoSec Medical System(OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that Punit Dhillon, President and CEO, has written an article for Today’s Medical Developments with the focus of addressing the medical industry’s challenge in finding a safe and effective method for delivering potentially useful agents to treat solid tumor cancers.

The article, titled “A Novel Delivery System,” details the components and processes governing use of the novel OncoSec Medical System (OMS) technology platform, which leverages electroporation technology to target tumors and deliver powerful cancer therapeutic agents without affecting surrounding healthy tissue. OncoSec is currently developing two platforms using its OMS technology which include the OMS ElectroImmunotherapy program, now undergoing three ongoing Phase II programs for rare and deadly skin cancers as well as the company’s late stage OMS ElectroChemotherapy program for the treatment of head and neck cancers.

To read the article in its entirety, please visit the following link:
http://www.onlinetmd.com/elecroporation-technology-cure-cancer.aspx

About OncoSec Medical Inc.

OncoSec Medical Incorporated (OTCBB: ONCS) develops novel OMS ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapieshave achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec’s clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy. More information is available at www.oncosec.com. Additional information may also be found at OncoSec’s Facebook , Twitter, and LinkedIn sites.

* * *

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward looking statements.” Forward looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties which may cause ourresults to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

NUMBERS ARE ONLY PART OF THE STORY
Numbers are important. They can be compared against others and tell us how far we have come and how far we have to go. Numbers help us measure our goals and aspirations, and show the world how we intend to reach them. They estimate odds and probabilities and they calculate results. They are necessarily impartial, rational and dispassionate.

But numbers only tell half the story.

They will never be able to put a value on the loss of a loved one, or convey the appreciation for every battle that is won against cancer. However, the largest number would still be too small to measure an empty space in a family photograph.

FROM BENCH TO BEDSIDE
At OncoSec, our dedication to research and development is underpinned by the belief that behind every statistic is a life, and behind every estimate, hope. These principles have guided our work – from a product based clinical development plan and enhancing our capacity to strengthening the scope and depth of our team.

We are committed to improving the quality of life for patients living with deadly skin cancers by providing them with safer and more effective approaches to treating these terrible diseases. The patient is our focus and our path has never been clearer as we move closer than ever to making our commitment a reality.

In less than one year, OncoSec not only initiated and completed the formation of the Company, but also committed to three Phase II clinical studies in rare and deadly skin cancers with significant unmet medical needs. This important milestone was the pinnacle of a number of accomplishments made throughout 2011 that advanced OncoSec from a start-up to a clinical-stage company.

2011 IN REVIEW
The formation of OncoSec in 2011 occurred through the acquisition of certain non-DNA vaccine technologies and intellectual property assets relating to the Company’s OMS ElectroOncology therapies for treating solid tumor cancers. With seed capital secured, the Company quickly moved to attract and acquire an experienced and respected management team and scientific and clinical advisory board.

The Company then established a robust clinical development plan based on its novel, first-in-class OMS ElectroImmunotherapy platform for the treatment of rare and deadly skin cancers, including (1) metastatic melanoma; (2) Merkel cell carcinoma; and (3) cutaneous T-cell lymphoma. OMS ElectroImmunotherapy uses electroporation to deliver, directly into the patient’s own cells, a gene, which expresses interleukin-12, a potent, naturally occurring protein that is central to the regulation of the body’s anti-cancer immune function. Preclinical and Phase I studies have shown that the therapy is safe, without toxic side effects, and has resulted in immune responses that produced both a local and systemic response against cancerous lesions. Positive clinical data of DNA-based IL-12, the first-ever to demonstrate electroporation-mediated delivery of a DNA plasmid designed to express a therapeutic protein in humans, was presented at the 2011 Annual Meeting of the American Society of Clinical Oncology. In the Phase I human study, 15% of patients demonstrated 100% clearance of distant, untreated metastatic melanoma (stage III/IV) tumors; in retrospect only 0.25% would be expected to spontaneous resolve on their own if left untreated. If OncoSec’s Phase II trials further validate this evidence, the DNA-based IL-12 ElectroImmunotherapy platform would represent an important advancement in the treatment of both local and metastatic cancers. All three Phase II studies will be physician-sponsored clinical trials.

This past year also demonstrated the Company’s ability to continue to create value from its advanced-stage OMS ElectroChemotherapy program for the treatment of primary and recurrent localized solid tumors. Since the acquisition of a clinical data set of over 400 patients, OncoSec has compiled, reviewed, and analyzed the data and presented preliminary results from previous Phase IV European head & neck cancer trials and a Phase I/II breast cancer trial. The preliminary data sets from the completed Phase III recurrent head and neck cancer studies carried out in the U.S. and a comprehensive review of the Phase IV European trials in recurrent and primary skin cancers and head & neck cancer are now being analyzed. The Company expects to share this information with potential partners for the continued development of this program.

ON THE FUTURE, PATIENTS – AND NUMBERS
While the near-term outlook for OncoSec is exciting, the long-term outlook may be even brighter. Our platform technology is novel and unique, and data from our OMS ElectroOncology therapies are first-in-class. Over the next 12 months we expect to have interim clinical data from all three of our Phase II trials. We have successfully made the transition to a clinical development company and are well positioned to capitalize on the opportunities for growth ahead of us.

HOW?
The Company will continue to build product value through next generation devices and drugs and generate additional intellectual property organically or through other in-licensing opportunities. In 2011, OncoSec established in-house capabilities to build, maintain and develop its own devices. In 2012, the Company expects to boost its capabilities by meeting additional stringent quality assurance standards and increasing manufacturing capabilities for its ongoing and future clinical trials through additional efficiencies and ability to scale up production as needed to support potential partners.

At OncoSec, we believe 2012 will continue the momentum gained in 2011: by maintaining a lean enterprise through outsourcing and cash flow management, while remaining flexible enough to respond to emerging opportunities; by collaborating with partners such as the University of California San Francisco, the University of Washington and the Fred Hutchinson Cancer Center in order to strengthen our treatment platforms; by creating value from our late-stage OMS ElectroChemotherapy program through potential partnering deals with regional or global partners; and by focusing on the health of the patient.

With our clinical studies off the ground, we look forward to treating the first patient with DNA-based IL-12 and moving ever closer to being able to improve lives with a potentially revolutionary treatment that could offer greater efficacy and safety than existing therapies. That we have advanced so far towards our goal underscores the hard work of the entire OncoSec team, scientific advisors, the Board of Directors, and the tremendous support of our investors. We are dedicated to bringing the entirety of our resources and expertise to try and meet the expectations of our shareholders and patients around the world.

February 3, 2012

Punit Dhillon
President & CEO

This letter contains certain forward-looking statements relating to our plans to develop our OMS ElectroOncology therapies. Actual events or results may differ from our expectations as a result of a number of factors, including the uncertainties inherent in clinical trials and product development programs (including, but not limited to, the fact that Phase I clinical results referenced in this letter may not be indicative of results achievable from testing in Phase II clinical trials) and the other factors set forth in detail in our Annual Report on Form 10-K for the year ended July 31, 2011 and other regulatory filings. There can be no assurance that any product in our product pipeline will be successfully developed or manufactured, or that final results of clinical studies will be supportive of regulatory approvals required to market licensed products. We encourage our shareholders to carefully review the section entitled “Risk Factors” in the Annual Report with which this letter is provided.

OncoSec – Positive Phase IV ElectroChemotherapy Clinical Data

OncoSec has continued to demonstrate a commitment to achieving our corporate milestones and confirming the company’s urgency for developing revolutionary targeted therapies using its proprietary electroporation delivery system, the OncoSec Medical System, or OMS. With our recent $7.75 million financing we are now poised to focus our resources on exceeding expectations and continuing to drive value from our novel OMS treatment platforms.

OMS ElectroChemotherapy: Targeted Ablation of Solid Tumor Cancers

Today, we announced positive data from our late-stage Phase IV pre-marketing study conducted in Europe at leading clinical centers of excellence using OncoSec’s OMS ElectroChemotherapy treatment platform for primary and recurrent squamous cell carcinoma of the head and neck (HNSCC). Click here for a full copy of the press release.

Interim analysis of this study indicated that the primary endpoint of 8-month local tumor control rate for primary and recurrent HNSCC was excellent with 46/49 (94%) and 12/21(57%) respectively. In addition, the secondary endpoint of preservation of organ function and appearance using established quality of life instruments demonstrated a positive outcome. The functional outcome measurement to evaluate quality of life, specifically any deterioration of swallowing function, normalcy of diet and eating in public was assessed by the subjective Performance Status Scale for Head and Neck cancer (PSSHN) and general QOL by the European Organization for Research and Treatment of Cancer Core QOL questionnaire (EORTC QLQ). HNSCC patients showed a mean overall score of 264 at baseline vs. 249 at 8 months (p=0.3412) indicating no significant difference in quality of life at 8 months following treatment with OMS ElectroChemotherapy, therefore providing an advantage in maintaining quality of life. Furthermore, evaluation of safety using the OMS ElectroChemotherapy for this patient population demonstrated that the treatment was safe and well-tolerated with no grade three or higher adverse events related to treatment during this study.

Secondary endpoints evaluated for this trial included Pharmacoeconomic factors (hospital costs, extent of medical interventions, medication use) and performance of the OncoSec Medical System and applicator. This data is being summarized in combination with the above results for final publication.

The impressive quality of life outcomes in conjunction with strong local tumor control responses are significant: the majority of patients treated in this study had advanced complicated tumors and the only alternative therapy would have been extensive surgery, with potential post-operative radiotherapy. Surgery may have precipitated collateral damage to surrounding tissues and vital structures. While post-treatment care could repair some of this damage, it may also result in further quality of life, physical and emotional burden on the patient and significant additional treatment costs.

In addition to these clinical results, we are preparing to present data from our Phase III head and neck cancer study carried out in the United States. This study was a randomized trial comparing preservation of function status after either OMS ElectroChemotherapy or surgery in patients with locally recurrent or second primary squamous cell carcinoma of the head and neck. These results will be presented at:

The 8th International Head and Neck Cancer Conference
Toronto Convention Center
Toronto, Canada
July 21-25, 2012

Poster Session
“Interim analysis of two randomized Phase 3 trials comparing electrochemotherapy to surgery in recurrent head and neck cancer”

OMS ElectroImmunotherapy: On-going Clinical Trials for Rare and Deadly Skin Cancers

Two Phase II clinical trials for metastatic melanoma and Merkel cell carcinoma are now underway, and several patients in both trials have already been dosed. We expect our third Phase II trial for cutaneous T-cell lymphoma to be initiated in the coming weeks. We expect enrollment for these trials to continue through 2012, however, preliminary results will be shared before the end of the year.

The media has picked up the enthusiasm for our clinical trials and technology with several news outlets covering stories about the company. Below is a sample of OncoSec’s recent news coverage:

San Diego Business Journal– The article, titled “OncoSec Inches Ahead on Skin Cancer Zapping Technology” discusses OncoSec’s development plan, highlighting the company’s OMS ElectroImmunotherapy program for the treatment of Merkel cell carcinoma, metastatic melanoma and cutaneous T-cell lymphoma. This article is only available online to subscribers of the San Diego Business Journal

The Journal- The article, titled “Fighting skin cancer with electroimmunotherapy,” outlines the rationale for the Phase II Merkel cell carcinoma study and describes the urgent need for a new therapy for this patient population.

Today’s Medical Developments– The article, titled “A Novel Delivery System,” details the components and processes governing use of the novel OncoSec Medical System (OMS) technology platform, which leverages electroporation technology to target tumors and deliver powerful cancer therapeutic agents without affecting surrounding healthy tissue.

Medical Device and Diagnostic Industry– The article titled “OncoSec Could Revolutionize Oncology Therapy,” details the company’s promising OMS ElectroOncology treatment platform, as well as the on-going Phase II clinical studies in metastatic melanoma and Merkel cell carcinoma.

If you have any questions about OncoSec or our current activities, please contact us at investors@oncosec.com. Thank you for your support.

Best,

Punit Dhillon
President & CEO

Preliminary Results of Phase IV Head & Neck Cancer Trial Demonstrate Primary Endpoint Was Achieved; Final Results of Phase I Breast Cancer Trial Show 77% Response Rate

SAN DIEGO, CA, September 26, 2011 — OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage OMS ElectroOncology™ therapies to treat solid tumor cancers, announced today clinical study results presented at the Fire, Ice and Beyond: The Future of Ablation Therapies conference in Las Vegas, NV, September 23-24. OncoSec’s exhibition highlighted a poster titled, “OMS ElectroChemotherapy: Targeted Ablation of Solid Tumors using Reversible Electroporation in Combination with Bleomycin,” which provided preliminary results from their Phase IV head and neck cancer trial and final clinical data from the Phase I breast cancer trials carried out in Europe using OncoSec’s OMS ElectroChemotherapy™ treatment approach.

Phase I Breast Cancer Study

The FDA-approved Phase I study of 13 patients with recurrent breast cancer treated with OncoSec’s OMS ElectroChemotherapy™ demonstrated that the therapy was safe, well-tolerated, and achieved a complete response rate of 77% (10/13) for all patients treated in this study.

The open-label, single-treatment trial in patients with recurrent breast cancer following partial or complete mastectomy used intratumoral administration of bleomycin followed by electroporation to significantly enhance uptake of the drug using OMS ElectroChemotherapy™. No treatment-related serious adverse events were observed. Non-serious adverse events were “unremarkable” during a 30-day follow-up period. Thirteen patients (15 tumors) were enrolled in this study. Excluding one patient lost to follow-up, 10 of the 12 evaluable patients (83%) met the criteria for Complete Response (CR) at 24 weeks.

“The result of this Phase I trial indicates the potential for this local treatment of recurrent breast cancer following partial or complete mastectomy and merits further evaluation,” stated Dr. Paul Goldfarb, OncoSec’s Medical Director.

Preliminary: Phase IV Head & Neck Cancer

This Phase IV registration trial carried out in Europe enrolled 92 patients (53 males and 39 females) with 66 patients followed for up to two years. Mean age at enrollment was 61.0 years (range 20 – 86 years). Seventy-six percent of tumors treated were primary cancers, and 23% were recurrent cancers, with a mean tumor volume for all cancers of 19 cm3. Treatment was found to be safe and well-tolerated with majority of adverse events being pain (77%), infection (50%), edema (48%), and dysphagia (30%). Patient survival following treatment at 8 months was 95% (87/92) and 86% (79/92) at 24 months. In addition, 83% (19/23) of patients with primary tumors treated with bleomycin and electroporation alone at 8 months were disease free. The mean time to onset of recurrence was 379 and 276 days for primary and recurrent disease, respectively. Preliminary analysis of this data demonstrates that the primary endpoint, local control of the tumor at 8 months, was achieved.

A subset of the study results from this Phase IV Recurrent and Primary Cutaneous Head & Neck Cancer Study was published by investigators from Orebro University Hospital in Orebro, Sweden in the medical journal Dermatological Surgery, August 2010, in a paper entitled, “Electroporation Therapy of Skin Cancer in the Head and Neck Area.” A second subset of results from this study was more recently published by the same group of investigators in the journal Acta Oto-Laryngologica, June 2011, in a paper entitled, “Electroporation therapy for T1 and T2 oral tongue cancer.”

Dr. Lennart Lofgren, principal investigator at Obrebro University Hospital and author of the above mentioned articles, said, “OMS ElectroChemotherapy™ has demonstrated promising safety and efficacy results in this patient population, in addition to providing superior functional and cosmetic outcomes for those patients with recurrent or otherwise complicated and difficult to treat skin cancers. This simple and novel delivery of bleomycin, an approved chemotherapeutic agent, through reversible electroporation has shown a marked improvement in potency, while delivering a much lower and safer concentration of the drug.”

“With positive results from these multiple clinical studies, OMS ElectroChemotherapy™ demonstrates clinical benefit for patients with manageable side effects,” said, Punit Dhillon, president and CEO. “We strongly believe in the clinical relevance of our therapeutic approach and believe these results demonstrate tolerability, efficacy and point to the combinability of this novel treatment approach with current available therapies for the management of local tumors. Clinical experience from these programs supports the uniqueness of OMS ElectroChemotherapy™ in its ability to achieve selective destruction of cancerous tumors while sparing healthy normal tissue including highly vascularized and innervated surrounding structures, providing physicians with an important flexible treatment alternative.”

About OncoSec Medical Inc.

OncoSec Medical Incorporated (OTCBB: ONCS) develops novel OMS ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapies have achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec’s clinical programs include three Phase II clinical trials. More information is available at www.oncosec.com.

* * *
This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward looking statements.” Forward looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

OncoSec to Present Phase IV Head and Neck Cancer and Phase I Breast Cancer Data on OMS ElectroChemotherapy™

San Diego, CA., September 22, 2011 — OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers, announced today that the company will be hosting an exhibition table at the 6th Fire, Ice and Beyond: The Future of Ablation Therapies conference in Las Vegas, NV, September 23-24. OncoSec’s exhibition will highlight a poster presentation providing preliminary results from their phase IV head and neck cancer and phase I breast cancer trials carried out in Europe using OncoSec’s OMS ElectroChemotherapy™ treatment approach.

“We are pleased to highlight at this important scientific conference the extent of our clinical development activities of our OMS ElectroChemotherapy™ program and begin to share validating data from prior clinical trials that supports the merits of the therapy,” said Punit Dhillon, president and CEO of OncoSec. “Our aim is to complete data analysis from the previous OMS ElectroChemotherapy™ programs and present this clinical data at applicable oncology and scientific meetings and seek a commercialization path for the product with the help of one or more industry partnerships from select geographic regions or globally.”

Through its asset acquisition, OncoSec has accumulated a significant database of clinical data in a variety of tumor types using the OMS ElectroChemotherapy™ therapeutic approach. To date OMS ElectroChemotherapy™ has been tested in several clinical trials ranging from Phase I through Phase IV conducted in 13 countries across over 50 sites. Human data has been collected in over 400 patients with cancers ranging from basal and squamous cell carcinomas, melanoma, adenocarcinoma, Kaposi’s sarcoma, pancreatic, hepatic, oral, and head and neck cancers.

The 6th Fire, Ice, and Beyond: The Future of Ablation Therapies is an advanced program presenting guidance in understanding the expanding field of new and cutting edge energy sources, combination therapies, embolic pharmaceuticals, treatment planning, fusion imaging, and navigation that make up Interventional Oncology procedures. This conference will be attended by physicians, scientists, and business executives in their areas of expertise.

About OncoSec Medical Inc.

OncoSec Medical Incorporated (OTCBB: ONCS) develops novel OMS ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapies have achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec’s clinical programs include three Phase II clinical trials. More information is available at www.oncosec.com.

* * *
This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward looking statements.” Forward looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Therapeutic oncology company moving into efficacy trials

SAN DIEGO, Ca, May 11, 2011 — OncoSec Medical Inc. (OTCBB: ONCS), a therapeutic oncology company developing innovative medical approaches to treat solid tumor cancers that have unmet medical needs, announced today the appointment of three members to its leadership team.Formed earlier this year, OncoSec expects to initiate Phase II clinical trials for its tumor-destroying, tissue-sparing ElectroOncology therapies before the end of this year.

OncoSec’s novel targeted tumor therapiesare designed to address the drawbacks of conventional therapies by being tissue sparing; providing potential functional, cosmetic and quality of life benefits; being less invasive and reducing side effects; and potentially reducing both treatment and post-treatment costs.Based on extensive past validating data from human studies, OncoSec expects to initiate advanced stage clinical studies for its ElectroImmunotherapy and ElectroChemotherapy programs by the end of 2011.

It is estimated that half of the 1.4 million cancers diagnosed each year in the United States are solid-tumor cancers. Cancers of the lung, prostate, colon, rectum or breast cancer are all solid tumor cancers. The National Institutes of Health estimated the annual cost of cancer to be $228.1 billion in 2008.

Today, Punit Dhillon, OncoSec’s co-founder, President and CEO, announced the following management appointments:

Dr. Michael Cross, Chief Business Officer

Michael Cross, PhD, a co-founder of OncoSec, will serve as Chief Business Officer. He will be responsible for business development, engineering operations, partnerships and fundraising, among other duties. Dr. Cross, who holds an MBA, has nearly two decades of life sciences venture capital and biotech industry experience. Prior to joining OncoSec, Dr. Cross was Vice President at GrowthWorks and Senior Vice President at Jovian Capital in Toronto. Previous to Jovian, Cross had lead operational responsibilities as COO of a public oncology company, Viventia Biotech, where he helped bring an anti-cancer antibody product into worldwide pivotal clinical trials.

Caryn Peterson, Vice President, Regulatory Affairs

Caryn Peterson brings to OncoSec more than 30 years of pharmaceutical industry experience in research and development, operations, and regulatory affairs. Prior to joining OncoSec, she led worldwide regulatory affairs for Syndax, a late-stage oncology company. Peterson also managed regulatory affairs at Ascenta Therapeutics and FeRx Inc., both oncology focused companies. She also worked in regulatory affairs at Amylin Pharmaceuticals, with a focus on first-in-class diabetes therapies. She is a founder and general partner of DSC-Associates, a pharmaceutical consulting group specializing in providing preclinical and clinical strategies to streamline product development.Ms. Peterson has authored several research publications and been a co-inventor on multiple patents.

Veronica Vallejo, CPA, Controller and Principal Financial Officer

Veronica Vallejo will serve as Controller and Principal Financial Officer. She has extensive experience in public accounting, most recently as a Senior Manager with Mayer Hoffman McCann P.C., a nationwide accounting firm.Ms. Vallejo has extensive experience in public company operations and all finance and accounting functions, including SEC reporting, compliance and internal controls.

These three leaders join Mr. Dhillon, co-founder, President and CEO, who has over 12 years of senior management experience in the biotech industry. He was recently VP Finance & Operations at Inovio Pharmaceuticals, Inc., where he played a pivotal role in raising over $125 million in funding. His operating and corporate finance experience includes product development, raising capital, merger and acquisition transactions and integration, partnering, clinical trials management, US and international regulatory oversight, and P&L and cash management. Mr. Dhillon also worked on numerous programs with the venture capital firm MDS Capital Corp., now Lumira Capital Corp.

About OncoSec Medical Inc.

OncoSec Medical Incorporated (OTC BB: ONCS.OB) is focused on designing, developing and commercializing innovative medical approaches to treat solid tumor cancers with unmet medical needs or where currently approved therapies are inadequate based on their efficacy level or side effect profile. The company’s therapies are based on the use of electroporation delivery in combination with an approved chemotherapeutic drug or a cytokine agent to treat solid tumors. More information is available at www.oncosec.com.

* * *
This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward looking statements.” Forward looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.


Real Time Web Analytics